Pancreatic Cancer Clinical Trial
Official title:
A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving MK0752 together with gemcitabine hydrochloride may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of giving MK0752
together with gemcitabine hydrochloride and to see how well it works in treating patients
with stage III or IV pancreatic cancer that cannot be removed by surgery.
OBJECTIVES:
Primary
- To determine the recommended phase II dose of MK0752 in combination with gemcitabine
hydrochloride in patients with unresectable stage III and IV pancreatic cancer. (Phase
I)
Secondary
- To evaluate tumor response in patients treated with this regimen.
- To determine the time to disease progression and 6 months and 1-year survival.
- To determine the percentage of change in CA19-9 levels.
Tertiary
- To assess target inhibition of MK0752 in plasma.
- To explore the feasibility of measuring MK0752 levels in tumor tissue.
- To establish relationships between measures of tumor expression of molecular target and
objective tumor response.
- To determine the pharmacokinetic profile of MK0752 in plasma when administered with and
without gemcitabine hydrochloride.
OUTLINE: This is a multicenter, phase I, dose-escalation study of MK0752 and gemcitabine
hydrochloride.
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients receive oral
MK0752 on days -14, -7, 1, 8, 15, and 22 in course 1 only and on days 1, 8, 15, and 22
beginning in course 2 and for all subsequent courses. Treatment with MK0752 and gemcitabine
hydrochloride repeats every 28 days* for 6 courses in the absence of disease progression or
unacceptable toxicity.
NOTE: *The first course is 42 days.
Patients undergo biopsy of tumor at baseline and on day -7. Tumor samples are analyzed to
determine Notch pathway inhibition via IHC and qualitative RT-PCR analysis and for MK0752
concentrations. Hair follicle (from the head) samples are collected at baseline and on day
-7 to determine Notch pathway inhibition via RT-PCR. Blood samples are collected
periodically to determine changes in CA 19-9 levels and MK0752 concentrations.
After completion of study treatment, patients are followed for 28 days and then every 2
months for 1 year. Patients will then be followed up as part of their normal clinic visits
for up to one year after the last patient was treated on the study.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
;
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|